Iodine (124I) Girentuximab

N/A

Report date: 2025/09/08 17:55:38

Base Information

Drug NameIodine (124I) Girentuximab
Drug Alias Name碘[124I]吉伦昔单抗Iodum (124I) girentuximabumiodine [124I] girentuximab吉仑妥昔单抗碘[124I]124I-Girentuximab +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive diagnostic agent +[5] 
Mechanisms of ActionPositron-emission tomography enhancersAnti-Carbonic anhydrase IX
TargetsCarbonic anhydrase IX
Therapy Area/IndicationsKidney NeoplasmsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesWilex AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHeidelberg Pharma AGTelix Pharmaceuticals Ltd
Active IndicationsN/A
Inactive IndicationsKidney NeoplasmsCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksKEGG